Ovarian Rejuvenation (PRP) for Diminished Ovarian Reserve: A Scientific Review of Efficacy

Q: Who is a suitable candidate for PRP therapy?

Currently, PRP therapy is primarily considered a research-stage approach for cases of severe diminished ovarian reserve or premature ovarian insufficiency where other standard fertility treatments have not been effective. It is not a generally recommended treatment.

Q: Is the safety of PRP therapy established?

Since the patient's own blood is used, the risk of rejection or severe side effects is considered low. However, common procedure-related risks such as infection or bleeding exist. Long-term safety data is still limited.

Q: Does PRP therapy guarantee pregnancy?

No. The 2024 meta-analysis did not report pregnancy or live birth outcomes at all, so there is currently no pooled evidence that PRP changes them. What it did find was a small rise in antral follicle count and in the number of oocytes retrieved, with no significant change in AMH.

Diminished ovarian reserve (DOR) is a significant concern for women planning future pregnancies. In recent years, Platelet-Rich Plasma (PRP) therapy, often referred to as "ovarian rejuvenation," has garnered attention. As a reproductive medicine specialist, I will explain its scientific mechanisms and the current evidence regarding its efficacy.

IMPORTANT: The information on PRP therapy for ovarian rejuvenation presented in this article is based on ongoing research. Its efficacy and safety have not yet been established by sufficient high-quality clinical trials. Further research is needed.

What is Ovarian Rejuvenation (PRP)? Understanding the Mechanism

PRP (Platelet-Rich Plasma) therapy involves preparing a plasma concentrate from the patient's own blood, rich in platelets. This PRP contains various growth factors that promote tissue repair and regeneration.

In reproductive medicine, it's hoped that injecting PRP into the ovaries of women with impaired ovarian function can activate dormant follicles or improve the microenvironment around the ovaries, leading to "ovarian rejuvenation."

The growth factors in PRP are suggested to promote cell proliferation and angiogenesis within the ovaries, potentially improving egg quality and quantity.

Diminished Ovarian Reserve and the Current Status of PRP Therapy

Diminished ovarian reserve refers to a condition where the number of eggs remaining in the ovaries decreases, or egg quality declines. This can be caused by aging or certain medical conditions.

PRP therapy is being explored as a potential new option, especially for women with severely diminished ovarian reserve or premature ovarian insufficiency (POI/POF) who have found standard fertility treatments unsuccessful.

However, current evidence for PRP therapy improving ovarian function or increasing pregnancy rates is limited. High-quality randomized controlled trials (RCTs) are scarce, and treatment protocols are not standardized, varying across clinics.

Long-term safety data is also still emerging. Therefore, when considering this treatment, it is crucial to have a thorough discussion with your doctor and understand its limitations and risks.

For general information on preconception care, you might find this article helpful. If you're feeling anxious about your TTC journey, remember that seeking professional support for your mental health is also valid.

Scientific Review: Current Knowledge on Efficacy

A 2024 meta-analysis pooled 14 studies and 1,632 patients (PMID: 38280991). The results split clearly by outcome.

AMH (Anti-Müllerian Hormone) — 11 studies, 2,099 participants. Mean difference 0.09 (95% CI −0.06 to 0.24, P = 0.25): no significant improvement
AFC (antral follicle count) — 6 studies, 1,399 participants. Mean difference 1.73 (95% CI 0.81 to 2.66, P < 0.001): a significant increase
Oocytes retrieved — 7 studies, 1,413 participants. Mean difference 1.21 (95% CI 0.48 to 1.94, P = 0.001): a significant increase

This needs reading carefully. You will see PRP described as raising AMH; in the pooled analysis, AMH did not change. What improved was antral follicle count and oocytes retrieved — and the latter by roughly one oocyte.

Most importantly, this analysis does not report an improvement in pregnancy rates or live birth rates. There is still a distance between retrieving one more egg and having a child.

It should also be said that most of the included studies had no control group, and PRP preparation methods were not standardised. Natural variation, placebo effect and selection of patients cannot be separated out.

A 2025 critical review summarises the state of the field this way: the encouraging reports are confined to case series and pilot studies, preparation methods, patient selection and endpoints vary too much to generalise from, and there is no established protocol, no controlled trial and no long-term safety data — the treatment is experimental at this stage (PMID: 40427083).

It has not been ruled out that PRP will become an effective treatment. But at present it is not a treatment with the evidence in place to justify paying for it.

If you are weighing the cost

PRP is a self-pay procedure at most clinics. If you are considering it, these are the questions to put to your doctor:

What is expected to improve, and by how much — AMH, AFC, or oocytes retrieved? As above, the answer differs by outcome.
Whether they can show evidence that pregnancy or birth rates improve — at present no pooled analysis has shown this.
How many procedures that clinic has done, and with what results — since the treatment is not standardised, the individual clinic's record matters.
What the same money would buy elsewhere — for instance, another retrieval cycle.

Frequently Asked Questions (FAQ)

Q1: Who is a suitable candidate for PRP therapy?

A1: Currently, PRP therapy is primarily considered a research-stage approach for cases of severe diminished ovarian reserve or premature ovarian insufficiency where other standard fertility treatments have not been effective. It is not a generally recommended treatment.

Q2: Is the safety of PRP therapy established?

A2: Since the patient's own blood is used, the risk of rejection or severe side effects is considered low. However, common procedure-related risks such as infection or bleeding exist. Long-term safety data is still limited.

Q3: Does PRP therapy guarantee pregnancy?

A3: No. The 2024 meta-analysis did not report pregnancy or live birth outcomes at all, so there is currently no pooled evidence that PRP changes them. What it did find was a small rise in antral follicle count and in the number of oocytes retrieved, with no significant change in AMH.

Summary

PRP for diminished ovarian reserve is an appealing idea, and using the patient's own blood makes it feel low-risk. The pooled evidence, though, is narrower than the marketing: no significant change in AMH, a small increase in antral follicle count and in oocytes retrieved, and no reported effect on pregnancy or live birth. A 2025 review describes the treatment as experimental, without an established protocol or long-term safety data.

If it is offered to you, it is reasonable to ask which of those numbers the clinic is expecting to move, and what the same money would buy in a more established treatment.

References

The value of intraovarian autologous platelet rich plasma in women with poor ovarian reserve or ovarian insufficiency: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024. PMID: 38280991 (14 studies, 1,632 patients; AMH not significant; pregnancy and live birth not reported)
Platelet-Rich Plasma (PRP) in Reproductive Medicine: A Critical Review of PRP Therapy in Low-Reserve and Premature Ovarian Insufficiency. Biomedicines. 2025. PMID: 40427083 (narrative review; the authors state the treatment is experimental at this stage)

Written by the same author — a general guide to preconception care and fertility planning: https://www.amazon.com/dp/B0F771VNV5?tag=ttcguide-enblog-22